A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality.
Latest Information Update: 06 Apr 2022
At a glance
- Drugs Aliskiren (Primary)
- Indications Diabetic angiopathies; Diabetic nephropathies; Hypertension in diabetes
- Focus Registrational; Therapeutic Use
- Acronyms ALTITUDE
- Sponsors Novartis; Novartis Pharmaceuticals
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 15 Sep 2017 Results of a post-hoc analysis assessing Michigan Neuropathy Screening Instrument (MNSI) prognostic information concerning cardiovascular risks, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 03 Nov 2012 Second interim analysis published in the New England Journal of Medicine.